Not Signed In - Anthera Receives FDA Approval To Begin Phase 2 'PLASMA' Trial With A-002 For Patients With Coronary Atherosclerosis
Sat, 06 Jan 2007 08:00 AM EST
... Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing anti-inflammatory drugs for chronic and acute diseases, announced today that the US Food and Drug Administration has approved its Investigational New Drug (IND) application for its lead cardiovascular compound A-002. [click link for full article] ...
Related Topics
- Atherosclerosis
- Clinical Trials
- Coronary Artery Disease
- Coronary Artery Diseases
- Coronary Heart Disease
- Coronary Disease
- Coronary Angioplasty
- Tarceva
- Acute Coronary Syndrome
- Arteriosclerosis/Atherosclerosis
- Coronary Occlusion
- Vaccine Testing & Approval
- Angioplasty
- Coronary Artery Bypass Graft
- What Your Female Patients Want to Know About Bladder Control
- Vaccinations For HIV/AIDs Patients
- Heart Diseases--Prevention
- Smoking Cessation and Continued Risk in Cancer Patients
- Food Recommendations: South Beach Diet - Phase 2
- Food Recommendations: South Beach Diet - Phase 1
email this page
print this page
bookmark this page
feedback on this page
